Lexicon Pharmaceuticals | LXRX - Equity Capital And Reserves


Lexicon Pharmaceuticals reported $202.86M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Illumina USD 2.68B 47M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
J&J USD 81.19B 358M Mar/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
MannKind USD -59.2M 8.17M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025